Glenmark Pharmaceuticals share news, announcements and annual reports
NSE: GLENMARKBSE: 532296Pharmaceuticals & BiotechnologyMid Cap
Glenmark Pharmaceuticals Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2000
Last close ₹2,382.00up ₹83.30 (3.62%)BSE ₹2,388.00
Share price at the NSE close on 2 Nov 2026. Previous close ₹2,298.70.
2 Nov: open ₹2,306.00, high ₹2,400.10, low ₹2,306.00
52-week range of traded prices to 2 Nov 2026
₹1,801.40Low, 7 Nov 2025₹2,537.60High, 28 Aug 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹67,226 Cr176th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 37.39
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 17.97
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.40
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.11%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.6%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 38.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 39.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 15,49,67347.5% delivered
Glenmark Pharmaceuticals orders, deals and press releases
594 filed, newest first. Page 9 of 12.
Jan 2013
Dec 2012
6 Dec · Business
Operations Committee of the Board of Directors of the Company, at its meeting held on December 06, 2012 allotted 13,100 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.
Nov 2012
Oct 2012
30 Oct · Business
Board of Directors of the Company, at its Meeting held on October 30, 2012 allotted 9,950 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.
Sep 2012
27 Sep · Business
Operations Committee of the Board of Directors of the Company, at its Meeting held on September 26, 2012 allotted 22,300 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.
Aug 2012
29 Aug · Business
Operations Committee of the Board of Directors of the Company, at its Meeting held on August 29, 2012 allotted 43,350 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.2 Aug · Business
Board of Directors of the Company, at its Meeting held on August 02, 2012 allotted 33,500 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.
Jun 2012
19 Jun · Business
Board of Directors of the Company, at its Operation Committee Meeting held on June 15, 2012 allotted 41,800 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.
May 2012
Apr 2012
Mar 2012
16 Mar · Business
Board of Directors of the Company, at its Operation Committee Meeting held on March 16, 2012 allotted 20,450 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.
Feb 2012
15 Feb · Business
Board of Directors of the Company, at its Meeting held on February 14, 2012, allotted 93,650 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.
Jan 2012
Dec 2011
23 Dec · Business
Board of Directors of the Company, at its Operations Committee Meeting held on December 23, 2011 allotted 8,650 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.
Nov 2011
11 Nov · Business
Board of Directors of the Company, at its Meeting held on November 09, 2011, allotted 33,950 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.
Sep 2011
2 Sep · Business
Board of Directors of the Company, at its Operations Committee Meeting held on August 30, 2011, allotted 26,050 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.
Aug 2011
Jul 2011
27 Jul · Business
Board of Directors of the Company, at its Meeting held on July 26, 2011, alloted 21,000 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.
Jun 2011
17 Jun · Business
Board of Directors of the Company at its Operations Committee meeting held on June 17, 2011 allotted 7,900 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.
May 2011
10 May · Business
Board of Directors of the Company at its meeting held on May 10, 2011 allotted 4,650 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.